SEC Form 4 · accession 0001144204-17-045902
Marker Therapeutics, Inc. · MRKR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Reddish
Director
Period of report
Aug 29, 2017
Accepted (ET)
Aug 30, 2017 · 4:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001094038
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 29, 2017 | A | 13,115 | $0.00 | A | 32,004 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the portion of the annual retainer for each non-employee director payable in immediately vested restricted, common stock under the Company's 2014 Omnibus Stock Ownership Plan and based on the closing price of $3.05 per share, on the day immediately preceding the date of the Company's 2017 annual meeting.